{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:40:01Z","timestamp":1773888001573,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017591","name":"Key Industry Innovation Chain of Shaanxi","doi-asserted-by":"publisher","award":["2024SF-ZDCYL-02-03"],"award-info":[{"award-number":["2024SF-ZDCYL-02-03"]}],"id":[{"id":"10.13039\/501100017591","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2025.101057","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:19:15Z","timestamp":1764692355000},"page":"101057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Profiles of blood biomarkers in lung cancer"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4104-6975","authenticated-orcid":false,"given":"Huange","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeqi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctarc.2025.101057_bib0001","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ctarc.2025.101057_bib0002","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin. Med. J."},{"issue":"10299","key":"10.1016\/j.ctarc.2025.101057_bib0003","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"issue":"10125","key":"10.1016\/j.ctarc.2025.101057_bib0004","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101057_bib0005","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/resp.12337","article-title":"Subcentimeter lung nodules stable for 2 years at LDCT: long-term follow-up using volumetry","volume":"19","author":"Shin","year":"2014","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/j.ctarc.2025.101057_bib0006","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.101057_bib0007","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3389\/fphys.2018.01710","article-title":"The evaluation of serum biomarkers for non-small cell lung cancer (NSCLC) diagnosis","volume":"9","author":"Fang","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ctarc.2025.101057_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108262","article-title":"Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer","volume":"210","author":"Wang","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ctarc.2025.101057_bib0009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2021.02.009","article-title":"A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer","volume":"233","author":"Ajona","year":"2021","journal-title":"Transl. Res."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101057_bib0010","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1164\/rccm.201210-1760OC","article-title":"Biomarkers to help guide management of patients with pulmonary nodules","volume":"188","author":"Patz","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Suppl 17","key":"10.1016\/j.ctarc.2025.101057_bib0011","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1002\/cncr.29551","article-title":"Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients","volume":"121","author":"Yang","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101057_bib0012","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/cncr.31020","article-title":"Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study","volume":"124","author":"Yang","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2025.101057_bib0013","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ebiom.2016.08.018","article-title":"Multiplexed serum biomarkers for the detection of lung cancer","volume":"11","author":"Ma","year":"2016","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/JTO.0b013e31827627f8","article-title":"Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules","volume":"8","author":"Daly","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101057_bib0015","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.trecan.2017.02.003","article-title":"Autoantibodies: opportunities for early cancer detection","volume":"3","author":"Macdonald","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ctarc.2025.101057_bib0016","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.lungcan.2016.07.018","article-title":"Autoantibodies against tumor-associated antigens in the early detection of lung cancer","volume":"99","author":"Dai","year":"2016","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101057_bib0017","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1384108","article-title":"Early detection of lung cancer by using an autoantibody panel in Chinese population","volume":"7","author":"Ren","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0018","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12890-024-03060-3","article-title":"The role of seven tumor-associated autoantibodies in the diagnosis, staging and treatment guidance of lung cancer","volume":"24","author":"Ma","year":"2024","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0019","doi-asserted-by":"crossref","first-page":"233","DOI":"10.21037\/tlcr-20-727","article-title":"Can autoantibody tests enhance lung cancer screening?-an evaluation of EarlyCDT\u00ae-Lung in context of the German Lung Cancer Screening Intervention Trial (LUSI)","volume":"10","author":"Gonz\u00e1lez Maldonado","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2013.10.008","article-title":"Audit of the autoantibody test, EarlyCDT\u00ae-lung, in 1600 patients: an evaluation of its performance in routine clinical practice","volume":"83","author":"Jett","year":"2014","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101057_bib0021","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jtho.2016.08.143","article-title":"Autoantibody signature enhances the positive predictive power of computed tomography and nodule-based risk models for detection of lung cancer","volume":"12","author":"Massion","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101057_bib0022","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtho.2015.11.011","article-title":"Comparative study of autoantibody responses between lung adenocarcinoma and benign pulmonary nodules","volume":"11","author":"Wang","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"207","key":"10.1016\/j.ctarc.2025.101057_bib0023","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007013","article-title":"A blood-based proteomic classifier for the molecular characterization of pulmonary nodules","volume":"5","author":"Li","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101057_bib0024","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.cllc.2016.09.012","article-title":"Development of a protein biomarker panel to detect non-small-cell lung cancer in Korea","volume":"18","author":"Jung","year":"2017","journal-title":"Clin. Lung Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101057_bib0025","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/JTO.0b013e31824ab6b0","article-title":"A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening","volume":"7","author":"Bigbee","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0026","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1465-9921-11-18","article-title":"Identification of lung cancer with high sensitivity and specificity by blood testing","volume":"11","author":"Leidinger","year":"2010","journal-title":"Respir. Res."},{"issue":"13","key":"10.1016\/j.ctarc.2025.101057_bib0027","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-09-3192","article-title":"Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer","volume":"16","author":"Farlow","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2025.101057_bib0028","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jtho.2017.01.017","article-title":"Rethinking autoantibody signature panels for cancer diagnosis","volume":"12","author":"Campa","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2025.101057_bib0029","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fmed.2020.00165","article-title":"Antinuclear antibodies with a homogeneous and speckled immunofluorescence pattern are associated with lack of cancer while those with a nucleolar pattern with the presence of cancer","volume":"7","author":"Gauderon","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101057_bib0030","first-page":"21","article-title":"The clinical significance of anti-mitotic spindle apparatus antibody (MSA) and anti-centromere antibody (ACA) detected in patients with small cell lung cancer (SCLC)","volume":"6","author":"Tan","year":"2017","journal-title":"Am. J. Clin. Exp. Immunol."},{"issue":"9","key":"10.1016\/j.ctarc.2025.101057_bib0031","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101057_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102674","article-title":"Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma","volume":"53","author":"Li","year":"2020","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101057_bib0033","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with Anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMa Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0034","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0003-4975(99)01198-4","article-title":"Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer","volume":"69","author":"Blaes","year":"2000","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.ctarc.2025.101057_bib0035","article-title":"The presence of autoantibodies is associated with improved overall survival in lung cancer patients","volume":"13","author":"Jing","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101057_bib0036","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.21873\/anticanres.14908","article-title":"Autoantibody positivity is a risk factor for chemotherapy-induced exacerbation of interstitial pneumonia in lung cancer","volume":"41","author":"Ito","year":"2021","journal-title":"Anticancer Res."},{"issue":"12","key":"10.1016\/j.ctarc.2025.101057_bib0037","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12032-020-01440-3","article-title":"Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients","volume":"37","author":"Morimoto","year":"2020","journal-title":"Med. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2025.101057_bib0038","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.21037\/tlcr-22-464","article-title":"Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study","volume":"11","author":"Zhang","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101057_bib0039","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2019.01.014","article-title":"Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies","volume":"130","author":"Yoneshima","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0040","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2204754","article-title":"Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)","volume":"12","author":"Daban","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctarc.2025.101057_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101388","article-title":"Development of autoantibody signatures for common cancers","volume":"47","author":"Kobayashi","year":"2020","journal-title":"Semin. Immunol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101057_bib0042","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","article-title":"Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets","volume":"35","author":"Cassetta","year":"2019","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101057_bib0043","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/SLA.0000000000001189","article-title":"Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific survival in resectable gastroesophageal junction and gastric adenocarcinoma","volume":"263","author":"Wang","year":"2016","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0044","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101057_bib0045","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/ijc.25991","article-title":"Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation","volume":"129","author":"Dumitru","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101057_bib0046","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.yexcr.2006.10.030","article-title":"Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response","volume":"313","author":"Peng","year":"2007","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101057_bib0047","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/path.2947","article-title":"Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4\/PI3K activation loop","volume":"225","author":"Wu","year":"2011","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101057_bib0048","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/JTO.0000000000000399","article-title":"Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer","volume":"10","author":"Cannon","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101057_bib0049","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.21037\/jtd-23-1169","article-title":"Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study","volume":"15","author":"Wang","year":"2023","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0050","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12885-021-08194-9","article-title":"A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers","volume":"21","author":"Ayers","year":"2021","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.ctarc.2025.101057_bib0051","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.3390\/curroncol31090367","article-title":"Complete blood count-based biomarkers as predictors of clinical outcomes in advanced non-small cell lung cancer patients with PD-L1 < 50% treated with first-line chemoimmunotherapy","volume":"31","author":"Putzu","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ctarc.2025.101057_bib0052","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.ctarc.2025.101057_bib0053","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00262-018-2182-4","article-title":"Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab","volume":"67","author":"Putzu","year":"2018","journal-title":"Cancer Immunol. Immunther."},{"issue":"12","key":"10.1016\/j.ctarc.2025.101057_bib0054","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00432-012-1281-4","article-title":"Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy","volume":"138","author":"Lee","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101057_bib0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the Lung Immune prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.ctarc.2025.101057_bib0056","article-title":"Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101057_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193018","article-title":"The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer","volume":"13","author":"Kiriu","year":"2018","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0058","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2019.1663666","article-title":"Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules","volume":"8","author":"Zhang","year":"2019","journal-title":"J. ExtraCell Vesicles"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0059","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40364-023-00517-1","article-title":"Identification of exosomal microRNA panel as diagnostic and prognostic biomarker for small cell lung cancer","volume":"11","author":"Kim","year":"2023","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0060","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12951-022-01366-0","article-title":"Identification and evaluation of circulating small extracellular vesicle microRNAs as diagnostic biomarkers for patients with indeterminate pulmonary nodules","volume":"20","author":"Zheng","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ctarc.2025.101057_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1027664","article-title":"Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer","volume":"12","author":"Fang","year":"2022","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101057_bib0062","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","article-title":"Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0063","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12916-024-03462-4","article-title":"Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with tislelizumaband chemotherapy","volume":"22","author":"Shan","year":"2024","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0064","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12935-024-03592-y","article-title":"Machine learning-based prognostic model of lactylation-related genes for predicting prognosis and immune infiltration in patients with lung adenocarcinoma","volume":"24","author":"Gao","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ctarc.2025.101057_bib0065","article-title":"Metabolomic machine learning-based model predicts efficacy of chemoimmunotherapy for advanced lung squamous cell carcinoma","volume":"16","author":"Zheng","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0066","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1186\/s12967-025-06872-x","article-title":"ImmuProgML: machine learning-based dissection of cancer-immune dynamics during tumor progression to improve immunotherapy","volume":"23","author":"Zhou","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101057_bib0067","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12890-024-03345-7","article-title":"Machine learning predictive models and risk factors for lymph node metastasis in non-small cell lung cancer","volume":"24","author":"Wu","year":"2024","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.ctarc.2025.101057_bib0068","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semcancer.2023.01.006","article-title":"Artificial intelligence in lung cancer diagnosis and prognosis: current application and future perspective","volume":"89","author":"Huang","year":"2023","journal-title":"Semin. Cancer Biol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:04:51Z","timestamp":1773871491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225001935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":68,"alternative-id":["S2468294225001935"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101057","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiles of blood biomarkers in lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101057"}}